Shares of Cencora COR lost 3.9% on Jun 27, followed by another 1.3% decline during the after-hours trading. This was likely due to the invalidation of a previously-settled opioid litigation by the Supreme Court. Meanwhile, an assumed softness in the retail pharmacy market is likely to have added to the pressure. However, Cencora has the ability to turn around with a multinational distribution footprint and a global platform of commercialization services that make it a natural partner for manufacturers bringing their products to the market. Moreover, improving patient access to medical care, enhanced economic conditions and population demographics are likely to favor the pharmaceutical segment in the upcoming quarters. Cencora’s shares have risen 11% year to date compared with the industry’s growth of 4.1%. the S&P 500 Index has increased 15.2% in the same period. Zacks Investment Research Image Source: Zacks Investment Research More on the Factors Per a CNN article, the recent Supreme Court ruling invalidated the $6 billion settlement related to the primary alleged entity in opioid abuse litigation, Purdue Pharma, which would have shielded its owner, the Sackler family, from future financial claims. The recent court ruling is separate from the 2021 settlement, wherein Johnson & Johnson and the three major drug distributors — Cencora (formerly AmerisourceBergen), McKesson MCK and Cardinal Health CAH — agreed to a $26 billion settlement to resolve allegations that helped fuel the opioid crisis. However, with the invalidation of one settlement raises concern for further court rulings in favor of opioid-abuse victims. The recent Supreme Court ruling may allow families hurt by the opioid crisis to once again pursue legal claims, especially against the Sackler family. This may have a spillover effect on other related companies. Moreover, four states opted not to join the national settlement in 2021 and were able to continue their legal fight. Cencora, McKesson, J&J and Cardinal Health have already set aside a reserve to meet the multi-year $26 billion settlement. Any invalidation of the settlement or a new settlement ruling may increase the burden for these companies. Moreover, this may lead to higher legal expenses. The stock’s decline is likely to have reflected the rising concern related to the opioid-abuse litigation. It may also have reflected an assumed weakness in the retail pharmacy market following lower-than-expected results of the largest global pharmaceutical wholesaler, Walgreens Boots WBA, leading to more than 22% decline in its share price on Jun 27. WBA is the biggest customer of Cencora. It accounted for nearly a quarter of Cencora’s total revenues in 2023. The weakness in Walgreens Boots’ quarterly performance should get reflected in COR’s third-quarter fiscal 2024 results. Apart from Cencora, the Supreme Court ruling and Walgreens Boots’ weak results have also led to a decline in the shares of other related companies like McKesson and Cardinal Health. Shares of MCK and CAH were down 1.1% and 1.5%, respectively, on Jun 27. Cencora, Inc. Price Cencora, Inc. Price Cencora, Inc. price | Cencora, Inc. Quote Zacks Rank Cencora currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Cardinal Health, Inc. (CAH):Free Stock Analysis Report McKesson Corporation (MCK):Free Stock Analysis Report Cencora, Inc. (COR):Free Stock Analysis Report Walgreens Boots Alliance, Inc. (WBA):Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
Cencora (COR) Stock Nosedives: Here's What Caused the Decline
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...